<SEC-DOCUMENT>0001493152-20-021822.txt : 20201117
<SEC-HEADER>0001493152-20-021822.hdr.sgml : 20201117
<ACCEPTANCE-DATETIME>20201117071944
ACCESSION NUMBER:		0001493152-20-021822
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201117
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201117
DATE AS OF CHANGE:		20201117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		201319256

	BUSINESS ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): November 17, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
                                         or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission
                                         </B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
        Number)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
                                         Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25
Recreation Park Drive, Unit 108</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hingham,
Massachusetts 02043</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Offices) (Zip Code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (781) 875-3605</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.01 par value</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBOT</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    7.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
    FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 17, 2020, Microbot Medical Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that it has received patents
in multiple jurisdictions, further demonstrating the Company&rsquo;s continued execution of expanding and protecting its Intellectual
Property (IP) portfolio. The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
press release furnished as Exhibit 99.1 to this Current Report on Form 8-K is incorporated herein by reference. The information
in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be &ldquo;filed&rdquo;
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(d)
Exhibits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Harel Gadot</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 17, 2020</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="A close up of a logo&#10;&#10;Description automatically generated" STYLE="height: 87px; width: 225px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Secures Patents in Multiple Global Jurisdictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HINGHAM,
Mass., November 17, 2020</B> &ndash; Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions,
further demonstrating the Company&rsquo;s continued execution of expanding and protecting its Intellectual Property (IP) portfolio.
The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;As
we continue to make progress on the development, clinical and regulatory fronts, it is encouraging that we are also achieving
our goals to broaden the protection of our novel technologies,&rdquo; commented Harel Gadot, CEO, President and Chairman. &ldquo;Strengthening
our IP portfolio is a critical component of Microbot&rsquo;s strategy for facilitating product evolution and maximizing future
commercial opportunities.&rdquo;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance 684 pertaining to the Company&rsquo;s Self-Cleaning Shunt
(SCS) device. The allowed patent application is a Continuation of a patent, issued on July 19, 2016, and covers a device for mitigating
occlusion in an implantable catheter. The claims are directed to a device comprising a tube having at least one drainage opening
disposed in its wall and configured for implantation within a body cavity, further comprising a cleaning element having at least
one cleaning protrusion extending into the opening and configured to move within the opening.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the European Patent Office (EPO) granted an EP Patent covering the Company&rsquo;s guidewire technology for use with endo-luminal
interventions, and related to the Company&rsquo;s LIBERTY<SUP>TM</SUP> development. This is the second European patent granted
for this unique technology and extends protection to include the device&rsquo;s current development, having a double guidewire
comprising a first hollow guidewire and a second guidewire deployed within the first guidewire, and an adjuster mechanism operable
to displace the second guidewire longitudinally relative to the first guidewire between at least three states.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot&rsquo;s current proprietary technological
platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes
for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical
is available at <U>http://www.microbotmedical.com</U>.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to
future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to
statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary
closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY<SUP>TM</SUP>,
the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical
and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and
ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot
Medical can be found under the heading &ldquo;Risk Factors&rdquo; in Microbot Medical&rsquo;s periodic reports filed with the
Securities and Exchange Commission (SEC), which are available on the SEC&rsquo;s web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking statements, except as required by law.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 5P#A P$1  (1 0,1 ?_$ +T  0 # 0$  P$!
M       '" D*!@$"!00# 0$  @(# 0$              0(#! 8'" D%$
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M'V^86+.6\2CI_J[3R7C&#,R,IYR!B=;<:4,M2N2OXMV$[K4=Q"^?Q7EDA_\
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M%I5;@O?.?AN?T\GUXO*3"<: @-]IR#Y6[0,:D [.9N''ZA8V8((ANJ<Y9=H
M!U<H%UU=^=[_ /9G"_C_ -Z\%B'XC#HW.&,9%PQ]ZC<Z^X21B]M5V9^3[#]X
M#6P=_LWF\I%(W>?;97G,#+VJN.%#&!7T.HKNX(Y9X0Y$1R+G'UQ8J2YTA.XJ
MLJJA'V1J8GRK%*R,LHG(IHG 0,HU46(40V,)1Z:[D[?=Y. ]RF:./7C6[LT>
M>SG'LW49Z@Q.-74ZN9J;XKI_GW:+G?;>77R*T+MI<?)=PGW;60=")6BC2>C7
MZ7>"LF @/P'?7::ZT6(_FR_X;X-_WSM_^&FVMFW_ &OHJNR6;GB5_CNK_P"Z
M6Z_UZ-TN,A\U5F:ZW-:RR)HB:(FB)HB:(JS\@>6.)>-2]=:Y)>2:+JT-WSN*
M0CD&!Q.UC5VC9VLHK(R,:@'8N_2*!"F,<0,([; (ZD-<[TBJBH&:\YQ]YM8.
MY+6ZT4;&\A-'LM1AHJ?E&<M'M44%8N76=H-EX]_'R$DT=G359G!8G<4Z0B7<
M/F#4EKF^H40$')6[U52FB+P&4\C06),>VW)-E*Y/!4Z)5F),C,I#.3-TU$TM
MD@4.1,!%14-Q,(  ;B/PU+07$-&90X8K.N'\M& YBR5^MMZW<'#J?L+&O$-$
MN:],*LU'JRB(R+IDSD_<C&M.SN64(4PD((#MK*87@5-%36%Y3)7EYQ+3+ ZA
M:]5S6HC)PHW<+A8%45.](XE.F9:(@9V&06*(;"4'BHE'H;8=PT$#S\%.L*<\
M&>2KCQFN-G-WDQ2K778P\P^J$TW(_=R,<0P)F>5F0BQ59S;=-4P%5 ?050W[
ME2)D^?571/;3"M5-<*J +YYA<2UF:<QM=J9[0W:+*)*."6%8HJ"10Q!*#B*K
MTQ#%4V#X)NER@(=3:D0O/A\U&L*U?%;GKA?E6[D*W657]5R#$M"R3RD6-1J9
MX[B_4!(TK7Y)FH=G.QR2Q@(J) 360,( JF3N#>KV%F=%((.2]!REY:XKXT!7
M(S),4XF"W9K*+M&0#%$8J-(=>.1<@Z&872:K*>O(IB5/81$ $?LU40B8%C@"
MWJ#B#]%(D=&X/:2'#(@THO(\6>=.%N2=SLV,,<PLG RE,KD98S-U20PPCB*E
M'3IN!(M6&=+(%<-7#<?63,1/M[RB CN.H]IL-(V@!H& & _0I,CI7%[R7/.9
M.)/U5G<G9AH&(H<TQ=YM*-)Z*KANQ(*1Y%VBWV]==%NHJBFDT0[@]1PN=)LF
M(@!E $0 9 )R52:+,*Y^8G$D&_7:5JJ&LJ*"IT_<EGG1P5 @CN/JP];EHTO3
M[4W*Q?N$=96P.=B<%76%/W%?R.8EY0WI;&$9!SU1O@5]S9F;!\NTEH:4BF3I
M)F],QEVQ&JZ;ULJN43(.&R!^P>XO<&^JOC+,U8$%?A9-\H&"\7WRUX_EXR<<
MRM0FI* DEBR,"Q(9_%.#M78)MGS])P5(5B#V&,4.\H@(=-6$+B-6%"A<!@OQ
M+5Y5<)06/:==V<'/D=W6)-+QM;LYTX261;@Y6:?^2CD)^1>$!1N8?7(@#02B
M&RPCN 0(7EQ'P4:PI1X:\\JAR_=Y,C(BHR50?XO4AQEW#V13?1$DUF69WJ+M
MDY59QCEH#8A.U8CA$@E-U 1+UU5["PT*D&J_RSAY$<"89748J2J=DE  PI)M
MGZ#%DY[=R =F<J;Z6DD!.&P+-V2C8P?A4'4-C<_((74P*QLS7RIXDYBGE[6P
MQ;.XCR(HN#M')V); :#E'#\@A[=Y8:U+5>(K5H."G4RJJK-_M^!TF.NG>X/8
M'@O<&3^83Q.V[DK?,R^M*13M>/2YVF@DH<?-YO@X+M[@7?3G7 8_Y?;RLW#C
M;JM?8W8]V!S#ZFM#J^W4?NX=2TJ=N/?DWR11]X/(P&SA0H=$IG=OB4#L;] 1
M!1[0E9V/44=+J,4 ,'J+N#NF@#T-)!N :ZK?R+OGV/I%S:V=RWM_'@+^UI^>
MA9T,\9]>D9EX!)&$I79S.-]E>]-9>&7 XGSQXU&QN36QF?U]AX]%3D&U &)B
M"^GE-SSBS/>%,'67&-K96!LC;K0I(L-P;342+FLMQ2))Q:IO<(%.("!%2]Z"
M@A\BA@ZZ]!]O.Y/#.Y.WOW#B%[%<A@'N1>B>(_"6%U)&TR+@"RN3BNA^==NN
M8]N;X;=RVRDMR\GVY?5!*!UBF;5CJ_NU#P,VC%4,\<-YB,3\IS93M1'"50J^
M*+:C+R*9F:*#1P^?1Q623EY(.V3%J5P<H[&44#X#L CTUSN=KG4TBJX0TTS6
MM<UYF,81TLHVBJ$M/1B:W9[EM9'R"JJ8"!1.DLO4BQYS;]0V5]/_ *8AUU3V
M'4QP*MK"N[QJYRX(Y/J+0U,FW,)>6;7WKRA6@C=E/F:%V!5_#*MW#J-L,:F<
M=C*M%3BF(_K"D'8-8W,<W,8*0X%6OG)Z&K,4\F[!)-(B)8)>L[?OEBH((E$0
M(0HF,.YU55# 1,A0$ZAQ I0$P@&J*5FQE_RGX+QI)NH:+;K662:&,FJDI(E8
MJE5(?M$#QT:PGI1L!OL*[2:J=>I-9!$\^"@N 4-0'F>Q6YD$V]AQK/-F)C@!
MWD#-H/'B9!'81)%ST97"N3  []I'/>/P !'IJ_L/^(5=86FV$.1&(>1-:/9\
M3W!E8FK50C>7C!*HQL%?>'+W RGH-V5-_&..WJ7O+V*!U(8P==87-+30X%6!
M!R7/[Y7LXX_S#<(*"KLF*-@Q%.6VC3,"](8\@^7"8: ]F$?0*HU91C-Q"'2*
M"R@+KBJ4Q2 0!'6U$QS!4Y%4?FJV>/'D73.*F6LDY.O;5>0AYO'C&O,V$6]C
MFTN9[%R#V46,BWD56Z3HJS=3M(!% -ZG0=3+&7D::*&D#-=6N&LK5G.&,*5E
MBG>\"M7J!8S\4G(I$1?H-WJ0*>W>))G533<MS")#@4YB@8!V$0ZZT^M%E4FZ
M(JC\\OX/>0/[OWW]<9:R1?B#YJKO2N,.092LN^CZ]!N08S%KM$+4HY\)>[V+
MBRS;>(]Z!?TSMDW1CE*/03 &^X=-;CB TDK&!4K;SDUXH,*<?N*\ED_'\S=%
M,D41A79&P2<Y87TG'VQ%\_C8R:0=QC@YFS<_<^%5 R0$%,Q  .@[:UH7N+_-
MDLA%0L46C6R3,G#TFJS#R#E<BV6O8^]\U<*H@FA9I9O'NCK)I'(5VF@W,=0$
ME.Y,QBAN ATUL/):TN&86,8FBVAY9^*_"?'#C&;*&.9>YFO=05JI;.\G;"]E
M6%L;3,@SAY,'#%T=1%FX2</BJH'2 O9V[#T';6M'*^H:[$*[A0+-3B3;9:C<
MM>-\]#.%6SI;)["MNA2.8GN8FR,WC"39+]O51!<H$,)1W#N( _9K/**QJ@S6
MMWFW_M/!7^Q[O_>=7UBM\RIDS;_3HJX>&A\VC.3N8I)X?TVL?A"/?.3@&XD;
MM)I^NN?[/PI)B.IGZ%2Q5-YC\I;1G>[6:=F)%T2I,C.)-.'16-[8Z*!5'D<T
M42 W8LT@XTZ;=ND/ZOUQ67$!45,;69C P4ZJ":J\O"OQ!PV:L5US,O)>WW%F
MXO4<C.UG'%-EUZ_&5R!>E!6-"3=M!([D955N)3*F,;M 1V  #6LZ9Y<:8!6:
M.I6A7&[Q=4GB[R+99IQ_D.UR]>:U*9K2-1MAR2;I@K+.&JYW+6;$".U6Y2MN
MWTE0/\=P,'PU1SW/]2D"AJL ^:(;\J<]] $1RG<?Z?\ UEQK;C] ^2Q=3\U8
M[@%XV$.9E-E\UY9R'<JQC\T](URBUBFO/IK^4:02QV3F8F94Q5')R*NB&!%
M@E33( =-Q$=89)G@EC<E<-J*JT7(3%=,\8V&YRAX=L=EGY[D!.OYN;E;@Z3?
MR98BJL(R,CX07)")&6BEI&40.NF;JL@W.D;<JA@&8RZ4^?(*SL LD,(X3R7R
M\SY!8CK%B7C)FR-GULR!D62)]3?05:9KIH.73<CCN*M*2#E3TT -NDB4H]I>
M@!J\KRQOEZJ@%31;16[P:T%A271\9YGR.&2&;!5=DYN+Y*8K,W)))"8K23C!
M2*+1J[4#L[T!(=+NW#X;:PMGD&>*M[;<QFL(VDC>L66XLC$/'M/R+0)Q[[5P
MS7.16)L,&[<,GS-02[%>QKIPU4;N$3@*3EL<2G*(#MK<J2#C@10^(Z_/ZX+$
M0/@#0U_I3$'Q&*TKY@16*ISCGQKY2XMI4%2IS.C61')-2CVQD*',2K&&2=R3
MA&MMS$;5Z8&8!3=Y&@W,8O\ K"*#UUYPYK]N?&>2[@>3<+N)N,\\B=JBO+*L
M;2^M1[T;" 6DYEE"<=0<,%W_ ,)^X#DO'=N_VWRZWAY'P=XTOM+RCW-;E_!D
M?6C@,@^HK326'%9NU6J5/)=SKM6?9#5PU77LQ'%OLM(1CJR.JY"O#J)MGM>>
MMTA8NTW+Q,2%.X3!RB4!,5,XE'7&+#O1W![4W3-@^X2Q+MH)#8=^LV:[=]<!
M^<C8*1N)S>QK'#-T5,5R?<.T/ ^YUF_?^P5Z!N3&ZIMBNW:+EG4_E'O-9&@9
M,>YS2<&2#);8V/PN8NE<6!;./F=;C8K4I"GE8)_8YMI:*;<UR(&63;./0 19
MD?G(*8*('*9$X]0Z"77IO:]YL]XL8MSVN>*YVZ9H=')&X/8]IR+7MJ#],C@5
MYIW';+_:;V7;=SAEM]Q@>6R1R-+'L<,PYKJ$?\,0L/8FPW7%MFCK=7'3NKY
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M:BRJ6]$51^>7\'O(']W[[^MLM9(OQ!\U5WI7'15O^*&*-P 0'-&.=P'X#_\
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M_+WC5CB=+6[OF2E5Z7,J")FSR1$Q$3B<$]G#E!-5N@!3F #&,8"D_2$.NNW
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J"]ICI8'_ *CL6GYG3J3A86[GU!7],' %-OW@7X#JOS4X?56 T1-$7__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
